Page 61 - AN-2-4

Advanced Neurology Genomic insights into Alzheimer

(with or without hemorrhage) and generally demonstrate resultant structure, and physicochemical and biochemical
greater Aβ deposition. These mutations predominantly properties) emerge as critical components in fAD.
occur within the Aβ peptide domain. It is important to acknowledge the limited literature on
At present, limited research has delved into genotype- clinical measures and phenotypes for certain mutations
phenotype interactions across multiple mutations, as included in this study, attributed to their scarcity in
discussed above, regarding the pathogenicity of AD reported cases. As a result, it became necessary to
resulting from mutations in the APP gene. Two analogous incorporate studies characterized by lower overall quality
studies have investigated genotype-phenotype interactions and smaller sample sizes, ensuring an adequate breadth of
on PSEN1 and PSEN2 . Although both studies comparative phenotypic data. Phenotypic findings derived
[57]
[58]
identified variations in pathogenesis and clinical outcomes from case studies were also integrated where essential,
for specific mutations, the scarcity of available phenotypic particularly in cases where only a limited number of
descriptions limited the extent of these studies, resulting families (1 – 2 families) with a specific mutation had been
in few evident clinical genotype-phenotype correlations . identified and studied for academic inclusion. Given the
[58]
However, genotype-phenotype interactions and rarity of certain APP mutation subtypes linked to fAD
correlations have been more extensively explored in various pathology, the availability of experimentally identified
familial pathologies resulting from germline mutations. toxicity data for these specific AD mutation subtypes is
The implications of these results across a broad spectrum notably constrained. These limitations hinder our capacity
of pathologies underscore the importance of deepening to concretely validate the accuracy of our modeled toxicity
our understanding of these interactions in AD, particularly findings. Nevertheless, it is imperative to emphasize that all
in genetically mediated cases such as those seen in fAD. models underwent rigorous accuracy testing in accordance
with the relevant parameters, as delineated in Section 3.
In a review article, researchers identified a definitive
[59]
link between the location of mutations in breast cancer In addition to analyzing the impact of mutations on
gene 1 (BRCA1) and breast cancer gene 2 (BRCA2) the overall physical and chemical properties of the entire
with exacerbated pathogenic outcomes in breast cancer APP, there exists an avenue for further research that delves
development. Notably, mutations occurring on exon 11 into the potential phenotypic implications arising from
exhibited a heightened propensity for inducing mutation- substituted amino acid residues. Such an inquiry would
mediated diseases. These mutations demonstrated a involve a comprehensive exploration of the physicochemical
consistent correlation with an earlier age of onset, as properties associated with these pathogenic mutations.
evidenced by multiple studies . A further study focused Undertaking further research in this realm holds the
[59]
on germline mutations of BRCA1 in breast and ovarian promise of improving our mechanistic understanding of
cancers further affirmed this correlation, linking the fAD. A more robust evaluation of how the AD phenotype
codon number of the gene mutation to the ratio of breast responds to different variants within potentially pathogenic
to ovarian cancer incidence . In concert with these gene sequences can significantly contribute to improving
[60]
studies on mutation location with the BRCA1 gene, future diagnostics and therapeutics for AD.
additional correlations emerged concerning variations in 5. Conclusion
the structural modeling of individual mutations on BRCA1
and their consequent physiological outcomes . Moreover, Our investigation has unveiled a significant correlation
[61]
the present study unveiled molecular and pathological between the location of genetic mutations within the protein
differences among mutations, underscoring the diverse sequence and specific physicochemical properties, as well
physiological outcomes associated with each mutation. as clinical presentations among different fAD subtypes.
This insight underscores the intricate relationship between
Similar correlations have been identified in Kirsten rat
sarcoma viral oncogene homolog (KRAS)-driven tumors. genetic variations and the resultant clinical heterogeneity
A study conducted by Hunter et al. indicated that assessing within the fAD spectrum.
the structural and biochemical properties of KRAS mutations Notably, mutations that exhibited higher structural
(genetic drivers in various cancers) can offer valuable insights similarity when superimposed tended to manifest
into the pathogenicity and potential therapeutic approaches analogous physical and clinical characteristics. This
for the resultant tumors . The discoveries elucidated in observation highlights the relevance of shared structural
[62]
these cancer studies highlight the potential implications features in predicting clinical outcomes across certain fAD
of advancing our understanding of genotype-phenotype subtypes. However, the converse is also true, as our analysis
interactions. Moreover, the complex intermediaries unveiled varying neuropathological findings that exhibited a
governing these relationships (including mutation location, stronger correlation with increasing epitope toxicity burden.

Volume 2 Issue 4 (2023) 16 https://doi.org/10.36922/an.1734